MS
MCID: MLT020
MIFTS: 72

Multiple Sclerosis (MS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Multiple Sclerosis

MalaCards integrated aliases for Multiple Sclerosis:

Name: Multiple Sclerosis 56 12 74 52 25 53 73 36 54 6 42 43 15 37 17 71 32
Ms 56 52 25 73
Multiple Sclerosis, Disease Progression, Modifier of 56 13
Multiple Sclerosis Modifier of Disease Progression 29 6
Disseminated Sclerosis 56 25
Multiple Sclerosis, Susceptibility to, 1 56
Multiple Sclerosis, Susceptibility to 56
Multiple Sclerosis Susceptibility to 39
Generalized Multiple Sclerosis 12
Multiple Sclerosis Variant 58
Multiple Sclerosis 1 56
Insular Sclerosis 12

Characteristics:

OMIM:

56
Inheritance:
multifactorial

Miscellaneous:
onset 20-55 years of age
women affected more than men (3:2)
association with the hla-drb1*1501-dqb1*0602 haplotype has been repeatedly demonstrated in high-risk (northern european) populations.


HPO:

31
multiple sclerosis:
Inheritance multifactorial inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:2377
OMIM 56 126200
OMIM Phenotypic Series 56 PS126200
KEGG 36 H01490
ICD9CM 34 340
NCIt 49 C3243
SNOMED-CT 67 24700007
ICD10 32 G35
Orphanet 58 ORPHA228145
MedGen 41 C1868685
UMLS 71 C0026769

Summaries for Multiple Sclerosis

Genetics Home Reference : 25 Multiple sclerosis is a condition characterized by areas of damage (lesions) on the brain and spinal cord. These lesions are associated with destruction of the covering that protects nerves and promotes the efficient transmission of nerve impulses (the myelin sheath) and damage to nerve cells. Multiple sclerosis is considered an autoimmune disorder; autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs, in this case tissues of the nervous system. Multiple sclerosis usually begins in early adulthood, between ages 20 and 40. The symptoms vary widely, and affected individuals can experience one or more effects of nervous system damage. Multiple sclerosis often causes sensory disturbances in the limbs, including a prickling or tingling sensation (paresthesia), numbness, pain, and itching. Some people experience Lhermitte sign, which is an electrical shock-like sensation that runs down the back and into the limbs. This sensation usually occurs when the head is bent forward. Problems with muscle control are common in people with multiple sclerosis. Affected individuals may have tremors, muscle stiffness (spasticity), exaggerated reflexes (hyperreflexia), weakness or partial paralysis of the muscles of the limbs, difficulty walking, or poor bladder control. Multiple sclerosis is also associated with vision problems, such as blurred or double vision or partial or complete vision loss. Infections that cause fever can make the symptoms worse. There are several forms of multiple sclerosis: relapsing-remitting MS, secondary progressive MS, primary progressive MS, and progressive relapsing MS. The most common is the relapsing-remitting form, which affects approximately 80 percent of people with multiple sclerosis. Individuals with this form of the condition have periods during which they experience symptoms, called clinical attacks, followed by periods without any symptoms (remission). The triggers of clinical attacks and remissions are unknown. After about 10 years, relapsing-remitting MS usually develops into another form of the disorder called secondary progressive MS. In this form, there are no remissions, and symptoms of the condition continually worsen. Primary progressive MS is the next most common form, affecting approximately 10 to 20 percent of people with multiple sclerosis. This form is characterized by constant symptoms that worsen over time, with no clinical attacks or remissions. Primary progressive MS typically begins later than the other forms, around age 40. Progressive relapsing MS is a rare form of multiple sclerosis that initially appears like primary progressive MS, with constant symptoms. However, people with progressive relapsing MS also experience clinical attacks of more severe symptoms.

MalaCards based summary : Multiple Sclerosis, also known as ms, is related to pediatric multiple sclerosis and hypersomnia, and has symptoms including seizures, tremor and back pain. An important gene associated with Multiple Sclerosis is PDCD1 (Programmed Cell Death 1), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and MicroRNAs in cancer. The drugs Dinoprostone and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include Neural Tube and Limb, and related phenotypes are muscle weakness and spasticity

Disease Ontology : 12 A demyelinating disease that involves damage to the fatty myelin sheaths around the axons of the brain and spinal cord resulting in demyelination and scarring.

NIH Rare Diseases : 52 Multiple sclerosis (MS) is a degenerative disorder that affects the central nervous system , specifically the brain and the spinal cord. The disorder is characterized by destruction of the myelin , the fatty tissue that surrounds and protects the nerve fibers and promotes the transmission of nerve impulses, and damage to nerve cells . The symptoms vary widely from person to person, and may include sensory disturbances in the limbs, problems with muscle control, tremors, muscle stiffness (spasticity ), exaggerated reflexes (hyperreflexia), weakness, difficulty walking, poor bladder control, and vision problems. Most patients have periods during which they have symptoms (clinical attacks). The clinical attacks are typically followed by periods without any symptoms (remission ). After several years, the symptoms worsen continuously. Multiple sclerosis is considered an autoimmune disorder but the exact cause is unknown. Risk factors for developing multiple sclerosis include genetic factors like changes in the HLA-DRB1 gene and in the IL7R gene and environmental factors , such as exposure to the Epstein-Barr virus , low levels of vitamin D, and smoking. The goal of treatment of MS is to decrease attacks and the inflammation within the central nervous system.

OMIM : 56 Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system (CNS) with various degrees of axonal damage. MS affects mainly young adults with predominance for females. The disorder often leads to substantial disability (summary by Bomprezzi et al., 2003). (126200)

MedlinePlus : 42 Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body, leading to the symptoms of MS. They can include Visual disturbances Muscle weakness Trouble with coordination and balance Sensations such as numbness, prickling, or "pins and needles" Thinking and memory problems No one knows what causes MS. It may be an autoimmune disease, which happens when your immune system attacks healthy cells in your body by mistake. Multiple sclerosis affects women more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak, or walk. There is no specific test for MS. Doctors use a medical history, physical exam, neurological exam, MRI, and other tests to diagnose it. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

NINDS : 53 An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.  Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is the nerve-insulating myelin that comes under assault. Such assaults may be linked to an unknown environmental trigger, perhaps a virus. Most people experience their first symptoms of MS between the ages of 20 and 40; the initial symptom of MS is often blurred or double vision, red-green color distortion, or even blindness in one eye.  Most MS patients experience muscle weakness in their extremities and difficulty with coordination and balance.  These symptoms may be severe enough to impair walking or even standing. In the worst cases, MS can produce partial or complete paralysis.  Most people with MS also exhibit paresthesias, transitory abnormal sensory feelings such as numbness, prickling, or "pins and needles" sensations.  Some may also experience pain.  Speech impediments, tremors, and dizziness are other frequent complaints. Occasionally, people with MS have hearing loss. Approximately half of all people with MS experience cognitive impairments such as difficulties with concentration, attention, memory, and poor judgment, but such symptoms are usually mild and are frequently overlooked.  Depression is another common feature of MS.

KEGG : 36 Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by inflammation, demyelination and axonal loss. This disease typically strikes young adults, especially women. There are four types of MS according to their relapsing or progressive pattern that include relapsing-remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), and progressive relapsing (PRMS). In most patients, the disease has a relapsing-remitting course during the first years. Within 10 years, approximately 50% of patients progress to SPMS. The aetiology of MS is not well understood, but it is likely multifactorial, combining both genetic and environmental factors. Recently, the literature on the risk factors for MS has grown substantially. They indicate that a combination of a genetic predisposition, exposure to Epstein-Barr virus, cigarette smoking, and reduced sunlight exposure/vitamin D levels is involved. Authorized first-line treatments are considered equally effective, and include interferon beta and glatiramer acetate. They are primarily directed against inflammation, and might fail to adequately control disease activity in some patients. In that case, it has been recommended to switch these patients early to a therapy of higher efficacy. Currently, 13 different drugs with ten different active components are licensed in the European Union (EU) and the United States (US) for the treatment of MS.

UniProtKB/Swiss-Prot : 73 Multiple sclerosis: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

Wikipedia : 74 Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the... more...

Related Diseases for Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2160)
# Related Disease Score Top Affiliating Genes
1 pediatric multiple sclerosis 35.0 HLA-DRB1 HLA-DQB1
2 hypersomnia 33.5 HLA-DRB1 HLA-DQB1
3 autoimmune hepatitis 31.8 PDCD1 HLA-DRB1 HLA-DQB1
4 hashimoto thyroiditis 31.1 MIR142 IFNG-AS1 HLA-DRB1 HLA-DQB1
5 psoriasis 31.0 MIR326 MIR20A MIR17 MIR142 HLA-DRB1
6 central nervous system disease 31.0 MIR223 MIR17 MIR145 MIR142
7 primary biliary cirrhosis 30.8 PDCD1 MIR326 MIR223 MIR20A MIR17 HLA-DRB1
8 severe cutaneous adverse reaction 30.7 PDCD1 HLA-DRB1 HLA-DQB1
9 primary adrenal insufficiency 30.7 HLA-DRB1 HLA-DQB1
10 autoimmune disease of central nervous system 30.6 MIR223 MIR142 HLA-DRB1
11 autoimmune hepatitis type 1 30.6 HLA-DRB1 HLA-DQB1
12 connective tissue disease 30.5 MIR223 MIR17 MIR145 MIR142 HLA-DRB1
13 pityriasis rosea 30.5 HLA-DRB1 HLA-DQB1
14 nervous system disease 30.3 MIR96 MIR223 MIR20A MIR17 MIR145 MIR142
15 rectum cancer 30.2 MIR20A MIR17 MIR145
16 esophageal disease 30.0 MIR223 MIR17 MIR145 MIR142
17 oral squamous cell carcinoma 30.0 MIR96 MIR223 MIR17 MIR145
18 endometriosis 30.0 MIR223 MIR20A MIR145 MIR142
19 diffuse large b-cell lymphoma 29.9 PDCD1 MIR17 MIR145 MIR142
20 eye disease 29.8 MIR223 MIR20B MIR20A MIR17 MIR142
21 pancreatic ductal adenocarcinoma 29.8 MIR96 MIR223 MIR145 MIR142
22 gastrointestinal system disease 29.7 MIR223 MIR20A MIR17 MIR145 MIR142
23 leukemia, chronic lymphocytic 29.7 MIR223 MIR20A MIR17 MIR145 MIR142
24 prostate disease 29.7 MIR223 MIR20A MIR17 MIR145 MIR142
25 arteries, anomalies of 29.6 MIR223 MIR17 MIR145 MIR142
26 intestinal disease 29.5 MIR20A MIR17 MIR145 MIR142
27 breast disease 29.5 MIR20A MIR17 MIR145 MIR142
28 bladder disease 29.4 MIR96 MIR17 MIR145 MIR142
29 lung cancer susceptibility 3 29.1 PDCD1 MIR96 MIR20B MIR17 MIR145 MIR142
30 cardiovascular system disease 29.1 MIR223 MIR17 MIR145 MIR142
31 immune system disease 28.5 MIR96 MIR223 MIR20B MIR20A MIR17 MIR145
32 relapsing-remitting multiple sclerosis 12.8
33 marburg acute multiple sclerosis 12.8
34 primary progressive multiple sclerosis 12.7
35 multiple sclerosis 5 12.7
36 secondary progressive multiple sclerosis 12.7
37 multiple sclerosis 3 12.7
38 progressive relapsing multiple sclerosis 12.6
39 multiple sclerosis 2 12.5
40 multiple sclerosis 4 12.4
41 multiple sclerosis-ichthyosis-factor viii deficiency syndrome 12.2
42 neuromyelitis optica 12.2
43 balo concentric sclerosis 12.1
44 leukodystrophy, demyelinating, adult-onset, autosomal dominant 12.1
45 autosomal dominant leukodystrophy with autonomic disease 11.9
46 optic neuritis 11.9
47 trigeminal neuralgia 11.7
48 spasticity 11.6
49 progressive multifocal leukoencephalopathy 11.6
50 leber optic atrophy 11.6

Comorbidity relations with Multiple Sclerosis via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Neurogenic Bladder Paraplegia
Trigeminal Neuralgia

Graphical network of the top 20 diseases related to Multiple Sclerosis:



Diseases related to Multiple Sclerosis

Symptoms & Phenotypes for Multiple Sclerosis

Human phenotypes related to Multiple Sclerosis:

31 (show all 10)
# Description HPO Frequency HPO Source Accession
1 muscle weakness 31 HP:0001324
2 spasticity 31 HP:0001257
3 depressivity 31 HP:0000716
4 paresthesia 31 HP:0003401
5 emotional lability 31 HP:0000712
6 diplopia 31 HP:0000651
7 urinary incontinence 31 HP:0000020
8 urinary hesitancy 31 HP:0000019
9 incoordination 31 HP:0002311
10 cns demyelination 31 HP:0007305

Symptoms via clinical synopsis from OMIM:

56
Neurologic Central Nervous System:
spasticity
emotional lability
depression
high intensity area in white matter on head mri
cognitive dysfunction
more
Genitourinary Bladder:
urinary incontinence
urinary hesitancy
incomplete bladder emptying

Laboratory Abnormalities:
increased csf immunoglobulin levels
oligoclonal bands in csf
myelin basic protein in csf

Head And Neck Eyes:
diplopia
vision loss, monocular

Neurologic Peripheral Nervous System:
incoordination
weakness
sensory loss
paresthesias

Clinical features from OMIM:

126200

UMLS symptoms related to Multiple Sclerosis:


seizures, tremor, back pain, headache, syncope, hemiplegia, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, muscle cramp

Drugs & Therapeutics for Multiple Sclerosis

Drugs for Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 549)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dinoprostone Approved Phase 4 363-24-6 5280360
2
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
3
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
4
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
7
Acyclovir Approved Phase 4 59277-89-3 2022
8
Cetirizine Approved Phase 4 83881-51-0 2678
9
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
10
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Montelukast Approved Phase 4 158966-92-8 5281040
13
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
14
Titanium dioxide Approved Phase 4 13463-67-7
15
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
16
Phylloquinone Approved, Investigational Phase 4 84-80-0
17
Calcium carbonate Approved, Investigational Phase 4 471-34-1
18
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
19
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
20
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
21
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
22
Acetaminophen Approved Phase 4 103-90-2 1983
23
Suvorexant Approved, Investigational Phase 4 1030377-33-3
24
Levetiracetam Approved Phase 4 102767-28-2 441341
25
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
26
Topiramate Approved Phase 4 97240-79-4 5284627
27
Donepezil Approved Phase 4 120014-06-4 3152
28
Memantine Approved, Investigational Phase 4 19982-08-2 4054
29
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
30
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
31
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
32
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
33
Amitriptyline Approved Phase 4 50-48-6 2160
34
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
35
Propranolol Approved, Investigational Phase 4 525-66-6 4946
36
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
37
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
38
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
39
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
40
Ocrelizumab Approved, Investigational Phase 4 637334-45-3
41
Ethanol Approved Phase 4 64-17-5 702
42
Citalopram Approved Phase 4 59729-33-8 2771
43
Phenylephrine Approved Phase 4 59-42-7 6041
44
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
45
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
46
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
47
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
48
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
49
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
50
Norepinephrine Approved Phase 4 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 2495)
# Name Status NCT ID Phase Drugs
1 Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
2 Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients Unknown status NCT01417273 Phase 4 Drug: placebo
3 Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
4 Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential Unknown status NCT02419378 Phase 4 Alemtuzumab
5 A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients With RRMS Transferred From Previous Treatment With Natalizumab to Gilenya® (Fingolimod) Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
6 Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
7 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
8 The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients Unknown status NCT01407211 Phase 4
9 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Unknown status NCT03092544 Phase 4 dimethyl fumarate
10 Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY) Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
11 Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
12 Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses Unknown status NCT03021317 Phase 4 ACTHar
13 Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
14 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
15 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
16 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
17 A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4 Fingolimod
18 A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT] Completed NCT03257358 Phase 4 Fingolimod
19 Fatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple Sclerosis Completed NCT00267319 Phase 4 Glatiramer acetate
20 A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01585298 Phase 4 FTY720
21 Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis Completed NCT00423527 Phase 4 levetiracetam
22 Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone Completed NCT00203021 Phase 4 Glatiramer acetate
23 A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France Completed NCT01420055 Phase 4 fingolimod
24 A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device Completed NCT01791244 Phase 4 Rebif®
25 A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis. Completed NCT01498887 Phase 4 Fingolimod (FTY720)
26 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
27 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis Completed NCT00381264 Phase 4 Cesamet™ (nabilone)
28 An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830 Completed NCT00915460 Phase 4 Interferon beta-1a (Avonex)
29 Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis Completed NCT01395316 Phase 4 Alemtuzumab
30 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT) Completed NCT01534182 Phase 4 Fingolimod;Interferon beta - 1a (IFN);Glatiramer acetate (GA)
31 A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
32 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
33 Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720) Completed NCT02720107 Phase 4 fingolimod
34 A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects Completed NCT00913666 Phase 4 Interferon beta-1a (Avonex)
35 An Open-Label, Randomized, Single Cross-Over Study of Isopropyl Alcohol Wipes Versus No Injection Site Preparation on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Completed NCT00220922 Phase 4
36 Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart™ Completed NCT02254304 Phase 4 Rebif
37 CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Completed NCT02499900 Phase 4 Copaxone®
38 Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis Completed NCT00367484 Phase 4
39 A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy. Completed NCT00112034 Phase 4 Methotrexate;IV methylprednisolone
40 An Open Label, Prospective Parallel Cohort Study Comparing A 90-day Copaxone® Adherence Enhancement Program Among Persons With Multiple Sclerosis Who Participate in Shared Solutions® Alone or in Partnership With Their MS Center Completed NCT00240006 Phase 4
41 A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting Completed NCT01930708 Phase 4 dimethyl fumarate
42 Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
43 A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis Completed NCT01356940 Phase 4 dalfampridine ER;placebo
44 Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®) Completed NCT00534261 Phase 4 Interferon beta-1a
45 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC) Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
46 A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC) Completed NCT01216072 Phase 4 Fingolimod;Standard MS DMTs
47 Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis Completed NCT00078338 Phase 4 Rebif®;Copaxone®
48 A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®). Completed NCT02142205 Phase 4
49 A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE) Completed NCT02125604 Phase 4 dimethyl fumarate
50 Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo

Search NIH Clinical Center for Multiple Sclerosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
Baclofen
CARBOXYMETHYLCELLULOSE CALCIUM
Cladribine
COBALAMIN CONCENTRATE
Cyclophosphamide
Daclizumab
Dantrolene
Dantrolene Sodium
Hydroxocobalamin
HYDROXOCOBALAMIN ACETATE
Interferon beta-1a
interferon beta-1b
mecobalamin
Mitoxantrone
Mitoxantrone Hydrochloride
natalizumab
Vitamin B 12

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Multiple Sclerosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Multiple Sclerosis:
Autologous bone marrow-derived hematopoietic stem cells for the treatment of multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for multiple sclerosis
Bone marrow-derived mesenchymal stem cell transplantation for treatment of multiple sclerosis
Bone marrow-derived stromal cells for multiple sclerosis
Epiblast stem cell-derived oligodendrocyte progenitor cells for multiple sclerosis
FCRx, bioengineered hematopoietic stem cells for immunological tolerance
Hematopoietic stem cells for multiple sclerosis
MultiStem, bone marrow-derived cells for neurological disorders
NU211-01/NU215-02, umbilical cord mesenchymal stem cells for multiple sclerosis and neuromyelitis optica
NurOwn, mesenchymal stem cells secreting NTF for neurodegenerative diseases
Peripheral blood-derived hematopoietic stem cells for treatment of multiple sclerosis
Placental-derived mesenchymal stem cells for treatment of multiple sclerosis
Stem cell-derived oligodendrocyte precursor cells for multiple sclerosis
Tcelna, autologous T-cell immunotherapy for multiple sclerosis
Umbilical cord tissue-derived mesenchymal stem cells for teatment of multiple sclerosis
Embryonic/Adult Cultured Cells Related to Multiple Sclerosis:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19378207
Bone marrow-derived mesenchymal stem cells PMIDs: 22277374
Bone marrow-derived mesenchymal stem cells PMIDs: 22277374 22236384 21366911
Bone marrow-derived mesenchymal stem cells (family)
Oligodendrocyte progenitor cells PMIDs: 21946668
Facilitating cells PMIDs: 17150368
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Umbilical cord-derived mesenchymal stem cells PMIDs: 20682053
Astrocyte-like cells PMIDs: 19603590 19127447
Peripheral blood-derived hematopoietic stem cells (family)
Placenta-derived mesenchymal stem cells PMIDs: 22638856
Oligodendrocyte precursor cells PMIDs: 19363151
Myelin-reactive T-cells PMIDs: 18465664 21563876 19230777
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: multiple sclerosis

Genetic Tests for Multiple Sclerosis

Genetic tests related to Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Multiple Sclerosis Modifier of Disease Progression 29

Anatomical Context for Multiple Sclerosis

MalaCards organs/tissues related to Multiple Sclerosis:

40
Brain, T Cells, Testes, Spinal Cord, Bone, B Cells, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Multiple Sclerosis:
# Tissue Anatomical CompartmentCell Relevance
1 Neural Tube Cortical Sub Ventricular Zone Adult Oligodendrocyte Precursor Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
3 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
4 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
5 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
6 Spinal Cord Spinal Cord White Matter Myelinating Oligodendrocyte Cells Affected by disease
7 Brain Forebrain White Matter Myelinating Oligodendrocyte Cells Affected by disease
8 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
16 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
17 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate

Publications for Multiple Sclerosis

Articles related to Multiple Sclerosis:

(show top 50) (show all 31441)
# Title Authors PMID Year
1
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. 54 61 6 56
15912506 2005
2
CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. 54 6 56 61
10803840 2000
3
A mutated CCR5 gene may have favorable prognostic implications in MS. 6 54 56
12874407 2003
4
APOE epsilon4 and the cognitive genetics of multiple sclerosis. 54 56 61
20479360 2010
5
The role of the CD58 locus in multiple sclerosis. 54 56 61
19237575 2009
6
Risk alleles for multiple sclerosis identified by a genomewide study. 56 54 61
17660530 2007
7
Cleavage of cystatin C is not associated with multiple sclerosis. 56 61 54
17006926 2007
8
Cystatin C in cerebrospinal fluid and multiple sclerosis. 61 56 54
16900522 2007
9
A second major histocompatibility complex susceptibility locus for multiple sclerosis. 54 56 61
17252545 2007
10
Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. 56 54 61
16437581 2006
11
A controlled trial of natalizumab for relapsing multiple sclerosis. 54 61 56
12510038 2003
12
No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. 56 61
23444327 2013
13
No evidence for a role of rare CYP27B1 functional variations in multiple sclerosis. 61 56
23483640 2013
14
Potassium channel KIR4.1 as an immune target in multiple sclerosis. 56 61
22784115 2012
15
Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. 56 61
22095036 2012
16
Rare variants in the CYP27B1 gene are associated with multiple sclerosis. 56 61
22190362 2011
17
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. 56 61
21833088 2011
18
Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. 56 61
21061396 2010
19
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis. 61 56
20697062 2010
20
Upregulation of K2P5.1 potassium channels in multiple sclerosis. 61 56
20582984 2010
21
Silencing Nogo-A promotes functional recovery in demyelinating disease. 56 54
20437585 2010
22
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. 61 56
20428171 2010
23
A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. 61 56
19888296 2010
24
What role for genetics in the prediction of multiple sclerosis? 56 61
20186855 2010
25
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. 56 61
19293837 2009
26
Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. 56 54
19786693 2009
27
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. 61 56
19525955 2009
28
Risk alleles for multiple sclerosis in multiplex families. 61 56
19506219 2009
29
HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. 56 54
18656179 2008
30
The immunogenetics of multiple sclerosis. 61 56
18461312 2008
31
Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. 56 61
18541802 2008
32
Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. 54 56
17568699 2007
33
Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. 61 56
17646631 2007
34
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. 61 56
17179460 2006
35
Functional epistasis on a common MHC haplotype associated with multiple sclerosis. 61 56
17006452 2006
36
CD24 Ala/Val polymorphism and multiple sclerosis. 61 56
16631259 2006
37
A second-generation genomic screen for multiple sclerosis. 61 56
15494893 2004
38
PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients. 56 54
15372250 2004
39
Association of APOE polymorphisms with disease severity in MS is limited to women. 56 54
15007140 2004
40
Neuroretinitis in patients with multiple sclerosis. 56 61
15019385 2004
41
Twin concordance and sibling recurrence rates in multiple sclerosis. 61 56
14569025 2003
42
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. 54 56
12533090 2003
43
Multiple susceptibility loci for multiple sclerosis. 56 61
12217953 2002
44
Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. 56 54
11836653 2002
45
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. 56 54
11721059 2001
46
Linkage and association analysis of chromosome 19q13 in multiple sclerosis. 61 56
11714099 2001
47
PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients. 56 54
11528386 2001
48
Does 77C-->G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus? 56 54
11548742 2001
49
A genome screen for multiple sclerosis in Sardinian multiplex families. 56 61
11528508 2001
50
A point mutation in PTPRC is associated with the development of multiple sclerosis. 54 56
11101853 2000